/
/
Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes
Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes image
Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes
Posted Nov 22, 2017

The Mayo Clinic performed a study to see whether treatment at centers with significant myeloma expertise mattered to myeloma patients' long-term survival. In the recent publication in the Journal of Clinical Oncologythe investigators used the National Cancer Database to identify patients diagnosed with multiple myeloma between 2003 and 2011. The patients were divided into quartiles of myeloma patients treated per year.

  • Q1 = facilities treating fewer than 3.6 patients per year
  • Q2 = facilities treating 3.6-6.1 patients per year
  • Q3 = facilities treating 6.1-10.3 patients per year
  • Q4 = facilities treating over 10.3 patients per year

The investigators then adjusted for clustering of patients within facilities, demographics (sex, age, race, ethinicity), socioeconomic (income, education, insurance type), geographic (area of residence, treatment facility location, travel distance), and comorbidity (Charlson-Deyo score) factors and year of diagnosis. The distribution of patients was:

  • Q1 = 5.2%
  • Q2 = 12.6%
  • Q3 = 21.9%
  • Q4 = 60.3%

Overall survival numbers were then compared.

  • Q1 = 26.9 months
  • Q2 = 29.1 months
  • Q3 = 31.9 months
  • Q4 = 49.1 months

Even the difference between an entire facility (with multiple hematologists and oncologists) treating between 3 and 10 patients, overall survival was doubled. At a large myeloma center like MD Anderson, Dana Farber, Emory, Mayo Clinic or UAMS, the myeloma specialists are treating between 600 - 3,000+ cases per year. Myeloma experts understand the latest development in myeloma therapy and the nuances of personalized care. Because they specialize in myeloma, they can stay up-to-date on a cancer where accelerated, rapid-fire advances are occurring. For general oncologists, this is virtually impossible when trying to treat a wide range of cancers (prostate, breast, colon, etc.). The study authors concluded:

Patients who were treated for MM at higher-volume facilities had a lower risk of mortality compared with those who were treated at lower-volume facilities.

Patients can successfully take advantage of both local care and myeloma expertise. Many patients will travel to consult with a myeloma expert who can give them treatment recommendations, strategy and craft a plan of attack. This plan can then be administered closer to home by a general oncologist. In this scenario, patients gain the expertise to extend their lives with the greatest convenience possible. You can find a myeloma specialist in our Myeloma Specialist Directory.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811